Recent Updates
Recently added Catalysts
IMRN Positive Sentiment

Immuron CEO Steven Lydeamore presented at AusBioInvest

Monday, October 30, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immuron Limited announced that its CEO, Steven Lydeamore, presented at the AusBioInvest 2023 event on October 30th. The presentation detailed the company's strategies and developments in the biopharmaceutical sector. Immuron is focused on developing orally delivered targeted polyclonal antibodies to treat infectious diseases. The company has made the presentation available on its website for public access.
Price reaction · baseline $1.65 (2023-10-27 close) · clean, no other IMRN news in the window
day 0 close
+2.7%
day 1
+3.6%
day 3
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Steven Lydeamore presented at a notable industry event, AusBioInvest 2023.
  • The presentation is publicly accessible on the company's website, promoting transparency.
  • Immuron is actively advancing its development of targeted polyclonal antibodies.

Full Press Release Details

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia.
A copy of the presentation being made at AusBioInvest 2023 is available on the Company’s website.
https://www.immuron.com.au/corporate-presentations/
This release has been authorised by the directors of Immuron Limited.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com

Frequently Asked Questions

When did Immuron's CEO present at AusBioInvest 2023?

The CEO presented on October 30, 2023, from 9:40 to 10:35 AM AEST.

Where was the AusBioInvest 2023 session held?

The session took place at Park Hyatt in Melbourne, Australia.

What is the main focus of Immuron Limited?

Immuron Limited focuses on developing oral targeted polyclonal antibodies.

How can I access Immuron's presentation?

The presentation is available on Immuron's website under corporate presentations.

What stock exchanges is Immuron listed on?

Immuron is listed on ASX and NASDAQ under the ticker IMC and IMRN.

ShareAdd on Google
Tags: IMRN Viatris Investor Conferences Healthcare Immuron AusBioInvest Steven Lydeamore biopharmaceutical polyclonal antibodies
Last updated: Oct 30, 2023

Biotech snapshot

Lead asset
TravelanPhase 2
Diarrhea →